GGrantIndex
← Search

Embryonic Stem Cell/ Transgenic Mice Shared Resource

$190,534P30FY2012CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

The Embryonic Stem Cell/Transqenic Mice (ES TGM) Shared Resource was reorganized in 2003, under the direction of Dr. Hong Wu (STT and GU) and the co-direction of Drs. Xin Liu and Meisheng Jiang. UCLA has provided new space for the ES cell facility and for the injection facility. The ES/TGM Shared Resource produces targeted genetic alterations in embryonic stem (ES) cells, knock-in mice, knock-out mice and transgenic mice for its clients. The Shared Resource also provides re-derivation services. Drs. Wu, Liu and Jiang provide consultation in vector design, experimental design, analysis of recombinant ES cells and analysis of chimeric offspring. The shared resource is designed to be as turn key for the investigator as possible. The ES service provides a series of alternative vectors for knock-in and knock-out constructs, ES cell lines, irradiated feeder cells, tested sera, mycoplasma testing, electroporation services and cloning of ES targeted cells. Investigators prepare the targeting vector, drop it off and identify appropriate clones by Southern blotting and/or PCR. Appropriate clones are delivered by the ES facility to the injection facility for blastocyst injection and investigators characterize progeny for germline transmission by genetic analysis of tail clips provided by the Shared Resource. The Transgenic facility also prepares transgenic mice with plasmid, BAG, and lentiviral vectors. Inbred strains are available for appropriate back crossing. The directors and the technical staff are experienced and experts in their fields. Turn-around times for ES cell delivery and for transgenic mouse delivery are close to the minimum times possible for the biological processes. Homologous recombination to produce targeted ES cell clones has been 100% successful and generation of genetically modified mouse strains is greater than 95%. The Shared Resource also works to establish new technologies and to integrate state-of-the-art advances (e.g., use of BAG and lentiviral vectors) into procedures available to clients. During the current CCSG cycle the ES/TGM Shared Resource has created 74 targeted strains and 85 transgenic strains; 24 Cancer Center members representing seven Program Areas have utilized the services of the ES TGM Shared Resource during the current CCSG cycle, to produce 65 percent of these mice. (Please also see Section 6,2.3 on Shared Resources in the History, Description, Essential Characteristics). 18 Cancer Center members representing 7 Cancer Center Program Areas utilized the services of the Embryonic Stem Cell/Transgenic Mouse Shared Resource during the reporting period. This is a continuing shared resource.

View original record on NIH RePORTER →